Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2020 16:02 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly...
July 10, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
July 07, 2020 22:24 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
July 06, 2020 07:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies...
May 29, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that is has finalized a process development and manufacturing agreement with Biogen Inc....
May 27, 2020 08:00 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection

SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody...
May 18, 2020 05:05 ET | Source: Vir Biotechnology, Inc.

Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature

Human antibody potently neutralizes SARS-CoV-2 and related viruses, suggesting high barrier to resistance Clinical testing expected to begin this summer in collaboration with GSK SAN FRANCISCO, May ...
May 12, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
May 08, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic,...
May 07, 2020 16:01 ET | Source: Vir Biotechnology, Inc.

Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...